Cipla Share Price
Sector: Biotechnology & Drugs
1500.50 +0.80 (0.05%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1491.40
Today’s High
1501.20
52 Week Low
1310.05
52 Week High
1702
1494.80 -5.10 (-0.34%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1491.10
Today’s High
1506
52 Week Low
1335
52 Week High
1702.05
Key Metrics
- Market Cap (In Cr) 121186.44
- Beta 0.39
- Div. Yield (%) 0.87
- P/B 3.88
- TTM P/E 22.09
- Peg Ratio 0.82
- Sector P/E 24.5
- D/E 0
- Open Price 1499.9
- Prev Close 1499.7
Cipla Analysis
Price Analysis
-
1 Week1.34%
-
3 Months2.77%
-
6 Month0.01%
-
YTD-1.9%
-
1 Year5.55%
Risk Meter
- 24% Low risk
- 24% Moderate risk
- 24% Balanced Risk
- 24% High risk
- 24% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 7
- 7
- 7
- 8
- Buy
- 12
- 12
- 12
- 12
- Hold
- 8
- 8
- 8
- 8
- Sell
- 6
- 4
- 4
- 4
- Strong Sell
- 0.00
- 1
- 1
- 1
- Total
- 33
- 32
- 32
- 33
Cipla News
Stocks to watch: Airtel, Tata Motors, HAL, Cipla among shares in focus today
1 min read . 14 May 2025'Don't expect impact of US tariff threat, price cuts on business'
3 min read . 13 May 2025Cipla Q4 Results: Profit jumps 30% YoY; declares dividend of ₹16
2 min read . 13 May 2025Stocks to watch: Tata Steek, Airtel, Paytm among shares in focus today
1 min read . 13 May 2025Cipla Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 27547.62
- Selling/ General/ Admin Expenses Total
- 4832.83
- Depreciation/ Amortization
- 1106.95
- Other Operating Expenses Total
- 6657.9
- Total Operating Expense
- 21526.67
- Operating Income
- 6020.95
- Net Income Before Taxes
- 6820.81
- Net Income
- 5272.52
- Diluted Normalized EPS
- 65.24
- Period
- 2025
- Total Assets
- 37387.04
- Total Liabilities
- 6193.59
- Total Equity
- 31193.45
- Tangible Book Valueper Share Common Eq
- 324.5
- Period
- 2025
- Cashfrom Operating Activities
- 5004.98
- Cashfrom Investing Activities
- -3691.14
- Cashfrom Financing Activities
- -1292.79
- Net Changein Cash
- 30.31
- Period
- 2024
- Total Revenue
- 25774.09
- Selling/ General/ Admin Expenses Total
- 8433.06
- Depreciation/ Amortization
- 939.1
- Other Operating Expenses Total
- 649.33
- Total Operating Expense
- 20714.98
- Operating Income
- 5059.11
- Net Income Before Taxes
- 5701.9
- Net Income
- 4121.55
- Diluted Normalized EPS
- 53.76
- Period
- 2024
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.41
- Period
- 2024
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023
- Total Revenue
- 22753.12
- Selling/ General/ Admin Expenses Total
- 7507.04
- Depreciation/ Amortization
- 1017.83
- Other Operating Expenses Total
- 511.6
- Total Operating Expense
- 19047.03
- Operating Income
- 3706.09
- Net Income Before Taxes
- 4038.35
- Net Income
- 2801.91
- Diluted Normalized EPS
- 37.37
- Period
- 2023
- Total Assets
- 29463.28
- Total Liabilities
- 6055.5
- Total Equity
- 23407.78
- Tangible Book Valueper Share Common Eq
- 234.08
- Period
- 2023
- Cashfrom Operating Activities
- 3237.65
- Cashfrom Investing Activities
- -2388.51
- Cashfrom Financing Activities
- -958.29
- Net Changein Cash
- -96.78
- Period
- 2022
- Total Revenue
- 21763.34
- Selling/ General/ Admin Expenses Total
- 6908.86
- Depreciation/ Amortization
- 987.83
- Other Operating Expenses Total
- 463.91
- Total Operating Expense
- 18430.6
- Operating Income
- 3332.74
- Net Income Before Taxes
- 3493.27
- Net Income
- 2516.75
- Diluted Normalized EPS
- 33.28
- Period
- 2022
- Total Assets
- 27101.12
- Total Liabilities
- 6259.43
- Total Equity
- 20841.69
- Tangible Book Valueper Share Common Eq
- 198.32
- Period
- 2022
- Cashfrom Operating Activities
- 3325.9
- Cashfrom Investing Activities
- -1871.88
- Cashfrom Financing Activities
- -1599.79
- Net Changein Cash
- -132.32
- Period
- 2021
- Total Revenue
- 19159.59
- Selling/ General/ Admin Expenses Total
- 6031.69
- Depreciation/ Amortization
- 1000.57
- Other Operating Expenses Total
- 399.33
- Total Operating Expense
- 15960.05
- Operating Income
- 3199.54
- Net Income Before Taxes
- 3290.06
- Net Income
- 2404.87
- Diluted Normalized EPS
- 30.35
- Period
- 2021
- Total Assets
- 25151.89
- Total Liabilities
- 6825.36
- Total Equity
- 18326.53
- Tangible Book Valueper Share Common Eq
- 167.29
- Period
- 2021
- Cashfrom Operating Activities
- 3755.2
- Cashfrom Investing Activities
- -2387.18
- Cashfrom Financing Activities
- -1329.9
- Net Changein Cash
- 50.91
- Period
- 2020
- Total Revenue
- 17131.99
- Selling/ General/ Admin Expenses Total
- 6203.89
- Depreciation/ Amortization
- 1097.31
- Other Operating Expenses Total
- 421.32
- Total Operating Expense
- 15091.19
- Operating Income
- 2040.8
- Net Income Before Taxes
- 2178.18
- Net Income
- 1546.52
- Diluted Normalized EPS
- 19.8
- Period
- 2020
- Total Assets
- 23662.56
- Total Liabilities
- 7899.56
- Total Equity
- 15763
- Tangible Book Valueper Share Common Eq
- 135.56
- Period
- 2020
- Cashfrom Operating Activities
- 3068.45
- Cashfrom Investing Activities
- 104.04
- Cashfrom Financing Activities
- -2948.82
- Net Changein Cash
- 234.02
- Period
- 2019
- Total Revenue
- 16362.41
- Selling/ General/ Admin Expenses Total
- 5710.55
- Depreciation/ Amortization
- 1095.66
- Other Operating Expenses Total
- 495.46
- Total Operating Expense
- 14585.29
- Operating Income
- 1777.12
- Net Income Before Taxes
- 2079.14
- Net Income
- 1527.7
- Diluted Normalized EPS
- 20.97
- Period
- 2019
- Total Assets
- 23963.32
- Total Liabilities
- 8951.04
- Total Equity
- 15012.28
- Tangible Book Valueper Share Common Eq
- 127.03
- Period
- 2019
- Cashfrom Operating Activities
- 1691.14
- Cashfrom Investing Activities
- -1668.68
- Cashfrom Financing Activities
- -348.72
- Net Changein Cash
- -345.11
- Period
- 2025-03-31
- Total Revenue
- 6729.69
- Selling/ General/ Admin Expenses Total
- 1233.1
- Depreciation/ Amortization
- 308.73
- Other Operating Expenses Total
- 1769.98
- Total Operating Expense
- 5500.83
- Operating Income
- 1228.86
- Net Income Before Taxes
- 1504.3
- Net Income
- 1221.84
- Diluted Normalized EPS
- 15.12
- Period
- 2025-03-31
- Total Assets
- 37387.04
- Total Liabilities
- 6193.59
- Total Equity
- 31193.45
- Tangible Book Valueper Share Common Eq
- 324.5
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 5004.98
- Cashfrom Investing Activities
- -3691.14
- Cashfrom Financing Activities
- -1292.79
- Net Changein Cash
- 30.31
- Period
- 2024-12-31
- Total Revenue
- 7072.97
- Selling/ General/ Admin Expenses Total
- 1197.62
- Depreciation/ Amortization
- 279.8
- Other Operating Expenses Total
- 1622.35
- Total Operating Expense
- 5363.85
- Operating Income
- 1709.12
- Net Income Before Taxes
- 1916.09
- Net Income
- 1570.51
- Diluted Normalized EPS
- 19.43
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 7051.02
- Selling/ General/ Admin Expenses Total
- 1207.88
- Depreciation/ Amortization
- 271.74
- Other Operating Expenses Total
- 1674.54
- Total Operating Expense
- 5437.17
- Operating Income
- 1613.85
- Net Income Before Taxes
- 1789.06
- Net Income
- 1302.53
- Diluted Normalized EPS
- 16.12
- Period
- 2024-09-30
- Total Assets
- 34655.28
- Total Liabilities
- 6293.18
- Total Equity
- 28362.1
- Tangible Book Valueper Share Common Eq
- 287.92
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 2055.44
- Cashfrom Investing Activities
- -710.31
- Cashfrom Financing Activities
- -1182.8
- Net Changein Cash
- 177.57
- Period
- 2024-06-30
- Total Revenue
- 6693.94
- Selling/ General/ Admin Expenses Total
- 1194.23
- Depreciation/ Amortization
- 246.68
- Other Operating Expenses Total
- 1591.03
- Total Operating Expense
- 5224.82
- Operating Income
- 1469.12
- Net Income Before Taxes
- 1611.36
- Net Income
- 1177.64
- Diluted Normalized EPS
- 14.57
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 6163.24
- Selling/ General/ Admin Expenses Total
- 1084.23
- Depreciation/ Amortization
- 288.34
- Other Operating Expenses Total
- 1713.03
- Total Operating Expense
- 5135.72
- Operating Income
- 1027.52
- Net Income Before Taxes
- 1259.26
- Net Income
- 939.04
- Diluted Normalized EPS
- 11.63
- Period
- 2024-03-31
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.41
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023-12-31
- Total Revenue
- 6603.81
- Selling/ General/ Admin Expenses Total
- 1068.13
- Depreciation/ Amortization
- 233.43
- Other Operating Expenses Total
- 1568.62
- Total Operating Expense
- 5284.53
- Operating Income
- 1319.28
- Net Income Before Taxes
- 1473.81
- Net Income
- 1055.9
- Diluted Normalized EPS
- 14.82
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Cipla Technical
Moving Average
SMA
- 5 Day1505.76
- 10 Day1505.68
- 20 Day1519.65
- 50 Day1480
- 100 Day1472.4
- 300 Day1518.78
Cipla Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1754.55
- 19.6
- 1.13
- 1960.2
- 1376.75
- 422227.13
- Divis Laboratories
- 6598.45
- 317.1
- 5.05
- 6448.75
- 3725.55
- 174639.38
- Cipla
- 1500.5
- 0.8
- 0.05
- 1702
- 1310.05
- 121186.44
- Torrent Pharmaceuticals
- 3281.7
- 17.15
- 0.53
- 3589.95
- 2573.4
- 111074.56
- Dr Reddys Laboratories
- 1234
- 3.5
- 0.28
- 1420.2
- 1025.9
- 103121.47
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 41.57
- 6.54
- 11.27
- 14.23
- Divis Laboratories
- 104
- 12.28
- 18.97
- 26.38
- Cipla
- 22.99
- 3.88
- 15.18
- 14.74
- Torrent Pharmaceuticals
- 68.96
- 16.13
- 20.64
- 13.18
- Dr Reddys Laboratories
- 18.11
- 3.05
- 17.62
- 15.81
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-May-25
- Audited Results & Final Dividend
- 28-Jan-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 25-Jan-24
- Quarterly Results
- 22-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 12-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 16-Jul-25
- 13-May-25
- AGM
- 15-Oct-24
- 17-Sept-24
- POM
- 20-Aug-24
- 10-May-24
- AGM
- 10-Aug-23
- 12-May-23
- AGM
- 26-Aug-22
- 29-Jul-22
- AGM
- 25-Aug-21
- 27-Jul-21
- AGM
- 27-Mar-21
- 23-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 13-May-25
- 27-Jun-25
- -
- 16
- 14-May-25
- 27-Jun-25
- -
- 3
- 10-May-24
- 02-Aug-24
- 02-Aug-24
- 13
- 12-May-23
- 21-Jul-23
- 21-Jul-23
- 8.5
- 27-Jul-22
- 10-Aug-22
- 08-Aug-22
- 5
- 14-May-21
- -
- 09-Aug-21
- 5


